Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 18
- Registration Number
- NCT02977507
- Locations
- 🇺🇸
Mount Sinai St. Luke's Hospital, New York, New York, United States
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 43
- Registration Number
- NCT02965846
- Locations
- 🇵🇭
The Medical City, Pasig City, Philippines
🇮🇹Ospedale San Giuseppe, Universita di Milano, Milano, Italy
🇩🇪Ludwig-Maximilians-University, Dept of Ophthalmology, Munich, Germany
Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- Conditions
- Interventions
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- Allergan
- Target Recruit Count
- 313
- Registration Number
- NCT02961764
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Tampa General Hospital, Tampa, Florida, United States
Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use
- Conditions
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Allergan
- Target Recruit Count
- 346
- Registration Number
- NCT02959983
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Gtc Research, Shawnee Mission, Kansas, United States
🇺🇸Pharmax Research Clinic Inc., Miami, Florida, United States
Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Allergan
- Target Recruit Count
- 246
- Registration Number
- NCT02951975
- Locations
- 🇫🇷
IOP Institut Ophtalmologique de Picardie, Amiens, France
🇫🇷CHU Amiens, Amiens, France
🇫🇷Hopital Hotel Dieu Et Hme, Nantes, France
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Allergan
- Target Recruit Count
- 185
- Registration Number
- NCT02910713
- Locations
- 🇺🇸
Nashville Vision Associates, Nashville, Tennessee, United States
🇺🇸Eye Care Institute, Louisville, Kentucky, United States
🇺🇸Total Eye Care, PA, Memphis, Tennessee, United States
Safety and Effectiveness of VYC-12 Hyaluronic Acid Injectable Gel for Treatment of Superficial Cutaneous Depressions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- Allergan
- Target Recruit Count
- 134
- Registration Number
- NCT02877069
- Locations
- 🇫🇷
Laboratoire Dermscan-Pharmascan, Lyon, Auvergne-Rhône-Alpes, France
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
- Conditions
- Interventions
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1254
- Registration Number
- NCT02873221
- Locations
- 🇺🇸
Kentucky Pediatric Research Inc, Bardstown, Kentucky, United States
🇺🇸Quest Research Institute, Farmington Hills, Michigan, United States
🇺🇸Aventura Neurological Associates, PA, Aventura, Florida, United States
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
- Conditions
- Interventions
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1686
- Registration Number
- NCT02867709
- Locations
- 🇺🇸
Cedars Sinai Pain Center, Los Angeles, California, United States
🇺🇸Rapid Medical Research, Inc., Cleveland, Ohio, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Allergan
- Target Recruit Count
- 118
- Registration Number
- NCT02863705
- Locations
- 🇰🇷
Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea, Republic of
🇰🇷Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea, Republic of
🇰🇷Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea, Republic of